Blood
Articles in this Issue
Real-world comparative outcomes of CAR-T cell therapy versus bispecific antibodies in patients with multiple myeloma
Abstract Introduction: The emergence of novel immunotherapies and cellular therapies has transformed the treatment landscape for hematologic...
Mortality outcomes compared to the general population among long-term Hodgkin lymphoma survivors: A population-based analysis
Abstract Background: Treatment advances have significantly increased cure and survival rates in Hodgkin lymphoma (HL), with 5-year relative...
Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells.
Abstract Introduction: Bruton's tyrosine kinase (BTK) plays a central role in oncogenic signaling in MYD88 mutated (MYD88Mut) B-cell maligna...
Home administration of isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study
Abstract Introduction: IRAKLIA (NCT05405166) is an ongoing, global, non-inferiority trial of isatuximab (Isa) subcutaneous (SC) administratio...
Improved outcomes with higher cumulative doses of cytarabine consolidation in older patients with acute myeloid leukemia
Abstract Introduction: Post-remission consolidation with intermediate to high dose cytarabine (IDAC/HIDAC) has shown to improve outcomes, co...
Effectiveness and toxicity of cyclophosphamide, etoposide, and prednisone as an outpatient oral chemotherapy regimen in elderly and frail patients with non-Hodgkin lymphoma
Abstract INTRODUCTION The management of non-Hodgkin lymphoma (NHL) in elderly or frail patients not eligible for intensive chemotherapy remai...
Changes in body composition during early phases of treatment and subsequent risk of relapse in childhood Hodgkin lymphoma
Abstract Introduction: About 15% of children with intermediate/high-risk Hodgkin lymphoma (HL) suffer a relapse; salvage requires high-inten...
Congenital factor II deficiency presenting with recurrent thrombosis
Abstract Congenital prothrombin (factor II) deficiency is a rare autosomal recessive coagulation disorder, here we report a pediatric adoles...
The impact of NR1I2 gene polymorphism and body weight on asciminib pharmacokinetics in patients with chronic myeloid leukemia
Abstract Introduction: Asciminib (ASC), the first STAMP inhibitor for chronic myeloid leukemia in chronic phase (CML-CP), has demonstrated s...
IFI16 drives bortezomib resistance in multiple myeloma via wnt/β-catenin pathway: A novel therapeutic target
Abstract BACKGROUND Multiple myeloma (MM) remains incurable due to inevitable therapeutic resistance, and Bortezomib (BT...
Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)
Abstract Background: Achieving minimal residual disease (MRD) negative status has been associated with favourable outcomes confirming its ut...
Monoclonal gammopathy-related coagulopathies: A systematic analysis
Abstract Background: Monoclonal Gammopathy (MG)-related coagulopathies have been described in several case reports and small series involvin...
Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe), report of primary endpoint, nordic myeloma study group 29/21
Abstract Background: Bortezomib-Lenalidomide-dexamethasone (VRd) is a standard therapy for newly diagnosed transplant-in...
Efficacy of iptacopan in treatment of transplant-associated thrombotic microangiopathy (TA-TMA) post-allogeneic hematopoietic stem cell transplantation: A case series analysis
Abstract Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is pivotal for treating blood disorders but is complicat...
Soluble factors in the AML secretome drive macrophage polarization toward an M2-like state promoting an immunosuppressive microenvironment
Abstract Tumor-secreted proteins are critical mediators through which cancer cells dynamically reshape and modulate their surrounding microe...
DNMT3A and NPM1 co-mutations in Acute Myeloid Leukemia (AML): A genomic landscape study
Abstract Background: Independent genomic alterations (GA) in the DNMT3A and NPM1 genes occur frequently in AML. While NPM1 mutation carries...
Building a community of hematology department heads to foster peer support and managerial innovation
Abstract Introduction Healthcare systems in many countries are facing a profound and persistent crisis, fueled by chronic underinvestment, w...
Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis
Abstract Myelofibrosis (MF) is characterized by clonal hematopoiesis, bone marrow (BM) fibrosis, and dysplastic megakaryocyte (MK) hyperplas...
Serum erythropoietin level as a selective pressure in clonal hematopoiesis: Insights into the mutational landscape of myeloid neoplasias
Abstract Outgrowth of a founder mutant clone is an initial event in leukemogenesis. The corresponding somatic hit likely conveys a fitness a...
A pilot study of low-dose sirolimus to increase hematopoietic function in patients with RUNX1 familial platelet disorder
Abstract Background: Familial Platelet Disorder with germline RUNX1 mutation (RUNX1-FPD) is a rare inherited syndrome characterized by throm...
Trial in progress: A phase 1b, open-label, multiple ascending dose study of OM336, a novel BCMAxCD3 T cell engager, in patients with relapsed/refractory autoimmune cytopenias (NCT07083960)
Abstract Background/Purpose: Autoimmune cytopenias (AICs), including immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA)...
Aggressive lymphomas that are treated early have worse outcomes: Counterintuitive results from a national database study.
Abstract Background: Early initiation of chemotherapy is widely believed to improve survival in aggressive lymphomas; however, the optimal ti...
Retrospective analysis of mortality and morbidity among thrombotic thrombocytopenia purpura presenting to Georgia cancer center
Abstract Introduction: Thrombotic thrombocytopenia purpura (TTP) is a serious blood disorder with mortalities reaching 90% in patients who ar...
Immunological responses to blinatumomab treatment in B-acute lymphoblastic leukaemia (B-ALL) patients - australasian leukemia and lymphoma group ALL08 blam study
Abstract Aim: Blinatumomab is an anti-CD19 bispecific T cell engager designed to bring together CD3+ T cells with CD19+ malignant B cell targ...
Survival trends in chronic lymphocytic leukemia before and after BTK inhibitors era: A SEER database analysis
Abstract Introduction: Significant advances have been made in the last decade in the treatment of Chronic Lymphocytic Leukemia (CLL). Bruton...